Cell therapies for hematological malignancies: don't forget non-gene-modified t cells

Cell therapy currently performs an important role in the treatment of patients with various hematological malignancies. The response to the cell therapy is regulated by multiple factors including the patient's immune system status, genetic profile, stage at diagnosis, age, and underlying diseas...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2018-05, Vol.32 (3), p.203-224
Main Authors: Grant, Melanie L., Bollard, Catherine M.
Format: Article
Language:English
Subjects:
Adoptive T cell therapy
Antigens, Neoplasm - immunology
Cell- and Tissue-Based Therapy - adverse effects
Cell- and Tissue-Based Therapy - methods
Combined Modality Therapy
EBV
Genetic Therapy
Hematologic Neoplasms - immunology
Hematologic Neoplasms - metabolism
Hematologic Neoplasms - therapy
Hematopoietic Stem Cell Transplantation
Humans
Immune System
Immunotherapy, Adoptive
Leukemia
Lymphocyte Depletion
Lymphoma
T-Cell Antigen Receptor Specificity - immunology
T-Lymphocytes - immunology
T-Lymphocytes - metabolism
Tissue Donors
Transplantation, Homologous
Tumor associated antigens
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell therapy currently performs an important role in the treatment of patients with various hematological malignancies. The response to the cell therapy is regulated by multiple factors including the patient's immune system status, genetic profile, stage at diagnosis, age, and underlying disease. Cell therapy that does not require genetic manipulation can be mediated by donor lymphocyte infusion strategies, selective depletion in the post-transplant setting and the ex vivo expansion of antigen-specific T cells. For hematologic malignancies, cell therapy is contributing to enhanced clinical responses and overall survival and the immune response to cell therapy is predictive of response in multiple cancer types. In this review we summarize the available T cell therapeutics that do not rely on gene engineering for the treatment of patients with blood cancers.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2017.11.004